Squamous cell carcinoma - Plaveiselcelcarcinoom
☆ Yn 'e 2022 Stiftung Warentest-resultaten út Dútslân wie de konsuminttefredenheid mei ModelDerm mar wat leger dan mei betelle telemedisynkonsultaasjes.
Squamous cell carcinoma well differentiated ― In neistlizzende aktinyske keratose wurdt waarnommen.
References
Squamous cell carcinoma (SCC) is de twadde meast foarkommende hûdkanker yn 'e Feriene Steaten, nei basal cell carcinoma. It begjint meastentiids út precancerous lesions neamd actinic keratosis , en kin ferspriede nei oare dielen fan it lichem. De wichtichste oarsaak is bleatstelling oan ultraviolet (UV) strieling fan 'e sinne, dy't oer de tiid opbout. Behanneling omfettet normaal sjirurgyske ferwidering, benammen foar SCC op 'e holle en nekke. Stralingstherapy is in opsje foar âldere pasjinten as dyjingen dy't gjin sjirurgy kinne hawwe. Immunosuppresje fergruttet it risiko fan SCC. Hoewol seldsum, kin SCC ferspriede, benammen yn pasjinten mei ferswakke ymmúnsystemen. Regelmjittige kontrôles en sinnebeskerming binne wichtich foar dyjingen mei SCC.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Squamous cell carcinoma of the skin or cutaneous squamous cell carcinoma is the second most common form of skin cancer in the United States, behind basal cell carcinoma. Squamous cell carcinoma has precursor lesions called actinic keratosis, exhibits tumor progression and has the potential to metastasize in the body. Ultraviolet (UV) solar radiation is the primary risk factor in the development of cutaneous squamous cell carcinoma and the cumulative exposure received over a lifetime plays a major part in the development of this cancer. Surgical excision is the primary treatment modality for cutaneous squamous cell carcinoma, with Mohs micrographic surgery being the preferred excisional technique for squamous cell carcinoma of the head and neck, and in other areas of high risk or squamous cell carcinoma with high-risk characteristics. Radiation therapy is reserved for squamous cell carcinoma in older patients or those who will not tolerate surgery, or when it has not been possible to obtain clear margins surgically. Adjuvant radiotherapy is commonly after surgical treatment in very high tumors. Immunosuppression significantly increases the risk of squamous cell carcinoma over the course of an individual’s life. Metastasis is uncommon for squamous cell carcinomas arising in areas of chronic sun exposure, but it can take place, and the risk is increased in immunosuppressed patients. Patients with cutaneous squamous cell carcinoma should be examined regularly and remember to use measures to protect from UV damage.
Cutaneous squamous cell carcinoma (CSCC) is de op ien nei meast foarkommende kanker by minsken, en syn oantallen geane omheech. Hoewol CSCC normaal in goedaardige klinyske gedrach sjen litte, kin it sawol lokaal as nei oare dielen fan it lichem ferspriede. Wittenskippers hawwe spesifike paden identifisearre belutsen by CSCC-ûntwikkeling, dy't liede ta nije behannelingen. It hege oantal mutaasjes en ferhege risiko yn immunosuppressive pasjinten hawwe de ûntwikkeling fan immunotherapy oandroegen. Dizze resinsje sjocht nei de genetyske woartels fan CSCC en de lêste behannelingen dy't rjochte binne op spesifike molekulen en it ymmúnsysteem.
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
Cutaneous squamous cell carcinoma (CSCC) is the second most frequent cancer in humans and its incidence continues to rise. Although CSCC usually display a benign clinical behavior, it can be both locally invasive and metastatic. The signaling pathways involved in CSCC development have given rise to targetable molecules in recent decades. In addition, the high mutational burden and increased risk of CSCC in patients under immunosuppression were part of the rationale for developing the immunotherapy for CSCC that has changed the therapeutic landscape. This review focuses on the molecular basis of CSCC and the current biology-based approaches of targeted therapies and immune checkpoint inhibitors
○ Diagnose en behanneling
#Dermoscopy
#Skin biopsy